Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies von Negrea, O. George, Allen, Steven L, Rai, Kanti R., Elstrom, Rebecca, Abassi, Rashid, Farber, Charles M, Teoh, Nick, Horne, Heather, Wegener, William A, Goldenberg, David M

Volltext

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP) von Saleh, Mansoor N, Liebman, Howard, Bernstein, Zale P., Negrea, O. George, Bussel, James B., Onyegbula, Anthony C., Farber, Charles M, Abassi, Rashid, Cosgriff, Thomas M., Pennington, Kenneth, Horne, Heather, Teoh, Nick, Gomaa, Asraf, Wegener, William A, Goldenberg, David M

Volltext

Low-Dose Humanized Anti-CD20 Monoclonal Antibody (MAb), Veltuzumab, in Adult Immune Thrombocytopenic Purpura (ITP): Initial Results of a Phase I/II Study von Liebman, Howard A., Saleh, Mansoor N., Abassi, Rashid, Cosgriff, Thomas M., Teoh, Nick, Leoni, Matthew J, Wegener, William, Goldenberg, David M

Volltext